Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Michael, Kulig"'
Autor:
Nina Paschke, Matthias Perleth, Michael Kulig, Anna Marie Passon, Sandra Schulz, Katja Matthias
Publikováno v:
Dtsch Arztebl Int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7ce9878cb9fd7dab95df87b7605f766
https://europepmc.org/articles/PMC8025936/
https://europepmc.org/articles/PMC8025936/
Autor:
Frank Peinemann, Nicolaus Kröger, Carmen Bartel, Ulrich Grouven, Max Pittler, Rudolf Erttmann, Michael Kulig
Publikováno v:
PLoS ONE, Vol 6, Iss 2, p e17127 (2011)
INTRODUCTION: Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The aim of this systematic review is to investigate whether high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (HSCT) in pa
Externí odkaz:
https://doaj.org/article/b6c54422b06244c5aff502745cf4ef61
Publikováno v:
Das Gesundheitswesen. 80:e54-e61
Hintergrund Der Gemeinsame Bundesausschuss (G-BA) fuhrt fur alle neu zugelassenen Arzneimittel eine (Zusatz)Nutzenbewertung durch (vgl. § 35a SGB V). Fur Arzneimittel zur Behandlung seltener Erkrankungen (sogenannte Orphan Drugs [OD]) gelten einige
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b346497adc99bd3fd7d5b60f7eebca09
https://doi.org/10.1055/s-0043-104696
https://doi.org/10.1055/s-0043-104696
Publikováno v:
Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)). 80(12)
Der Gemeinsame Bundesausschuss (G-BA) führt für alle neu zugelassenen Arzneimittel eine (Zusatz)Nutzenbewertung durch (vgl. § 35a SGB V). Für Arzneimittel zur Behandlung seltener Erkrankungen (sogenannte Orphan Drugs [OD]) gelten einige Sonderreg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::64c6292380b54aa8edcdfa6b970cb96e
https://pubmed.ncbi.nlm.nih.gov/28521378
https://pubmed.ncbi.nlm.nih.gov/28521378
Autor:
Matthias Perleth, Gero Langer, Joerg J Meerpohl, Michael Kulig, Holger J. Schünemann, Angela Kaminski-Hartenthaler, Gerald Gartlehner
Publikováno v:
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 106:677-688
GRADE suggests that examination of 95% confidence intervals (CIs) provides the optimal primary approach to decisions regarding imprecision. For practice guidelines, rating down the quality of evidence (i.e., confidence in estimates of effect) is requ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79c9b91b59865c002358ba64ecf288bf
https://doi.org/10.1016/j.zefq.2012.10.016
https://doi.org/10.1016/j.zefq.2012.10.016
Autor:
Markus Lüngen, Holger Pfaff, Andreas Gerber, Michael Kulig, Anna Marie Passon, Milly Anna Schröer-Günther
Publikováno v:
European Journal of Integrative Medicine. 1:125-130
Introduction The Finnish prevention policy as well as the Finnish preventative interventions are widely recognized as a model for other countries. This qualitative interview study has the objective of shedding light on the political, organizational a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a64f3758a2a3ac79f299cacd867d8e49
https://doi.org/10.1016/j.eujim.2009.08.158
https://doi.org/10.1016/j.eujim.2009.08.158
Autor:
Ulrich Wahn, Thomas Keil, S.N. Willich, Stephanie Roll, Renate Nickel, Michael Kulig, Steffen Lau, Bodo Niggemann, Christoph Grüber
Publikováno v:
Allergy. 64:445-451
Background: The role of passive smoking for allergies and asthma in children above the age of 3 years remains unclear and possible interactive effects with parental allergies have not been formally evaluated in long-term studies. To examine the inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::361c9d03a9b007587c89d00ac3e490b7
https://doi.org/10.1111/j.1398-9995.2008.01867.x
https://doi.org/10.1111/j.1398-9995.2008.01867.x
Publikováno v:
Health Research Policy and Systems
Background Coverage decisions determining the benefit baskets of health systems have been increasingly relying on evidence regarding patient benefit and costs. Relevant structures, methodologies, and processes have especially been established for pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4739f8f531ec55ac58b670385db4d6
https://doi.org/10.1186/s12961-015-0028-5
https://doi.org/10.1186/s12961-015-0028-5
Autor:
M Vieth, Wolfgang Meyer-Sabellek, Peter Malfertheiner, D. Jaspersen, S.N. Willich, T Lind, Andreas Leodolter, Joachim Labenz, Manfred Stolte, D. Lindner, Michael Kulig, M Nocon
Publikováno v:
Zeitschrift für Gastroenterologie. 41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aac9b22eb2ed0ab4ee52bd8dfaa8eb25
https://doi.org/10.1055/s-0035-1555221
https://doi.org/10.1055/s-0035-1555221
Autor:
Esben Eller, Carsten Bindslev-Jensen, S Schmid, A. von Berg, Ulrich Wahn, Adnan Custovic, Bert Brunekreef, Steffen Lau, Magnus Wickman, M P Fantini, Joachim Heinrich, A. H. Wijga, Ursula Krämer, Stefan N. Willich, K. C. Lødrup Carlsen, K-H. Carlsen, S. Halken, Henriette A. Smit, A Høst, Michael Kulig, Christina Bollrath, Inger Kull, Angela Simpson, Thomas Keil
Publikováno v:
Allergy. 61:1104-1111
BACKGROUND: The Global Allergy and Asthma European Network (GA2LEN) is a consortium of 26 leading European research centres committed to establish a European research area of excellence in the field of allergy and asthma. AIM: One of the GA2LEN work
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd2f2c1edf03a77a0aac416069fb154
https://doi.org/10.1111/j.1398-9995.2006.01167.x
https://doi.org/10.1111/j.1398-9995.2006.01167.x